Skip to content

Clinical Impact of HOME Oxygen SATURation Measurement (SATURHOME)

Clinical Impact of Home Oxygen Saturation Measurement in Patients With Interstitial Lung Disease: Quality of Live, Health Care Use, Score of Anxiety, Depression and Dyspnea and Physical Activity Level

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04624191
Acronym
SATURHOME
Enrollment
100
Registered
2020-11-10
Start date
2020-11-11
Completion date
2023-06-30
Last updated
2021-10-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Interstitial Lung Disease

Keywords

Saturometry at home, Quality of life, Heath care use, Physical activity level

Brief summary

The use of saturometry at home is more and more widespread in patients suffering from interstitial pulmonary diseases (IPD), the patients seeing it as reassurance and a concrete way to follow the evolution of their disease. However, there are no studies evaluating the real clinical benefit of taking saturation at home in this population. In addition, clinical experience seems rather to demonstrate an increase in the anxiety level and the number of clinically unnecessary consultations related to the use of this measure. The secondary objectives are to determine the impact of this measurement on: (1) the health care use (telephone calls, medical consultations and hospitalizations), (2) dyspnea score, (3) the anxiety and depression score (HADS score) and (4) the physical activity level. The exploratory objectives will be to determine if the measurement of saturation at home makes it possible to (1) predict the occurrence of acute exacerbations of fibrosis, (2) effectively predict the decline in respiratory function tests and (3) 1-year mortality. The investigator will also assess whether this measure makes it possible to screen patients with oxygen therapy needs at home. The investigator hypothesize that measuring oxygen saturation at home will lead to a significant deterioration in quality of life, an increase in the use of health care, a significant increase in the rate of anxiety and depression, dyspnea and a decrease in the physical activity level.

Detailed description

Measurement tools 1. Quality of life: King's Brief Interstitial Lung Disease 2. Anxiety and depression score: HADS score 3. Dyspnea score : UCSD questionnaire 4. Physical activity level during 7 days: MoveMonitor by McRoberts 5. Home base saturation: Nonin Ny vantagr 9590 6. Disease evolution : complete lung function (plethymography, sprimoetry, DLCO), 6-minute walking test (following the ATS recommandation)

Interventions

OTHERSaturation at home

Clinical benefit of taking saturation at home in interstitial lung disease

Sponsors

Fondation IUCPQ
CollaboratorOTHER
Laval University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Fibrosing interstitial lung disease * Saturation below 90% during the 6-minute walk test * Clinically stable

Exclusion criteria

* Oxygen dependent at rest

Design outcomes

Primary

MeasureTime frameDescription
Quality of life by questionnaire1 yearImpact of home base saturometry on quality of life

Secondary

MeasureTime frameDescription
Dyspnea score1 yearImpact of home base saturometry on dyspnea score with the University of California, San Diego Shortness of breath Questionnaire (UCSD) in a scale between 0 to 120 where 120 is the worst score.
Anxiety and depression score1 yearImpact of home base saturometry on anxiety and depression score with the Hospital Anxiety and Depression Scale Questionnaire (HADs) in a scale between 0 to 42, where 42 is the worst score.
Physical activity level1 yearImpact of home base saturometry on physical activity level measure by accelerometer (McRoberts) and define by steps number.
Energy expenditure1 yearImpact of home base saturometry on energy expenditure (number of kilocalories burn by day), measure by accelerometer (McRoberts).
Health care use (phone calls, medical consultation)1 yearImpact of home base saturometry on health car use as number and principal reason for : telephone calls, medical consultations and hospitalizations.

Other

MeasureTime frameDescription
Mortality1 yearImpact of home base saturometry on 1-year mortality prediction
Pulmonary function decline1 yearImpact of home base saturometry on predict the decline in respiratory function tests, principally the forced vital capacity.
Acute exacerbation1 yearImpact of home base saturometry on predict the occurrence of acute exacerbations of fibrosis. Occurence: number of exacerbation of fibrosis during the year.

Countries

Canada

Contacts

Primary ContactGeneviève Dion
geneviève.dion@criucpq.ulaval.ca418-656-8711
Backup ContactJany Harvey, M.Sc.
jany.harvey@criucpq.ulaval.ca418-656-8711

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026